Xerecept Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Undetermined
  • Financing Rounds
  • 2

Xerecept General Information

Description

A steroid used to reduce brain swelling associated with tumors. Xerecept owned by Neurobiological Tech is used on pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with cerebral tumors

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 2000 Powell Street
  • Suite 800
  • Emeryville, CA 94608
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xerecept Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xerecept‘s full profile, request access.

Request a free trial

Xerecept Executive Team (5)

Name Title Board Seat Contact Info
David Levy Vice President
Abraham Cohen Chairman
Paul Freiman President & Chief Executive Officer
To view Xerecept’s complete executive team members history, request access »

Xerecept Board Members (1)

Name Representing Role Since
0000000 00000 Xerecept Chairman 000 0000
To view Xerecept’s complete board members history, request access »

Xerecept Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xerecept‘s full profile, request access.

Request a free trial